A readout from the first late-stage clinical trial intended to treat the fatty liver disease known as NASH has delivered disappointing results.
Gilead Sciences said Monday that its experimental drug, called selonsertib, failed to improve liver scarring compared to a placebo in a Phase 3 clinical trial. The study enrolled nearly 900 patients with compensated cirrhosis, an advanced form of NASH at higher risk for liver-related death.
Shares of Gilead fell 4 percent on Monday night following the disclosure of the results. The setback is particularly discouraging because Gilead has invested heavily in a pipeline of NASH drugs, hoping clinical success will translate into new revenue and earnings growth.
About the Author Reprints
When a forex account holder posts an advertisement on Craigslist, the web 2 .
0 creates an anonymous email address contact info
for him. If the conventional charge to mow a lawn within your area
is $40, and you also want a specific thing that sells on Craigslist for $40, you might desire to suggest a
good trade. craigslist nationwide search To add an image in your ad
on Craigslist is quite simple. Compose an e-mail message addressed to “[email protected]
My brother recommended I may like this blog. He was totally right.
This put up truly made my day. You can not consider just how much time I had spent for this information! Thanks!카지노톡
In October, McDonald’s Chief Executive Officer Steve Easterbrook told analysts that Chicken McNugget sales rose
10 percent two months after one clean food announcement.
Man I really want a successful DC movie franchise but I don have much hope.
How much exercise reverses fatty liver disease? Is it only related to obesity? What about familial high cholesterol?
At end of 2019, Genfit will announce results P3 / Elafibranor. Nash.
It should works as P2 was ok.
What is your feeling on ICPT? Do you think they have a chance or is all Nash drugs a hoax?
When will Genfit announce results from their P3 trial?